Reexposure to heparin of patients with heparin-associated antibodies.
Four patients with heparin-associated antiplatelet antibodies who were not receiving platelet function-inhibiting agents received heparin during surgery, angiography, or hemodialysis. Three of the four patients had complications that were attributed to heparin-induced platelet aggregation. The complications included a superficial femoral artery thrombosis, a thrombotic stroke after a carotid endarterectomy, and recurring thrombosis of a graft inserted for dialysis. Nine patients received aspirin (325 mg b.i.d.) or dipyridamole (Persantine) (200 to 300 mg daily) before reexposure to 5000 to 12,000 units of heparin during 11 vascular procedures. The procedures included two carotid endarterectomies, three aortofemoral bypasses, one femoropopliteal bypass, two femorotibial in situ saphenous vein bypasses, one iliofemoral thrombectomy, one bilateral iliac artery angioplasty, and one axillobifemoral bypass. Platelet counts averaged 173,000/mm3 before heparin reexposure, fell to an average of 86,000/mm3 within 24 hours of heparin reexposure, and returned to normal within 48 hours after the reexposure. None of these patients had a thromboembolic or hemorrhagic complication. Patients with heparin-associated antiplatelet antibodies are at risk for developing thrombocytopenia and thromboembolic complications on reexposure to heparin. The platelet function-inhibiting agents, aspirin and Persantine, protect the patients from the thromboembolic complications but not the thrombocytopenia associated with limited heparin reexposure.
Laster
J
J
Department of Surgery, University of Missouri, Columbia, Health Science Center, Columbia 65212.
Elfrink
R
R
Silver
D
D
D000792:Angiography; D000906:Antibodies / Q000032:analysis*; D001792:Blood Platelets / Q000276:immunology; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D006801:Humans; D007430:Intraoperative Care; D007431:Intraoperative Complications / Q000209:etiology / Q000517:prevention & control; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010976:Platelet Count / Q000187:drug effects; D006435:Renal Dialysis; D013921:Thrombocytopenia / Q000139:chemically induced / Q000276:immunology; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control; D014656:Vascular Surgical Procedures
D000906:Antibodies; D010975:Platelet Aggregation Inhibitors; D006493:Heparin